Bone metastatic disease: Taking aim at new therapeutic targets

Current Medicinal Chemistry

Volumn 18, Issue 20, 2011, Pages 3093-3115

  Coluzzi, F ^a   Di Bussolo, E ^a   Mandatori, I ^a   Mattia, C ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Bone; Bone resorption; Cancer; Cathepsin K; CXCR4; Denosumab; ETAR; Metastasis; Molecular targeted therapy; Osteoclasts; Pain; RANKL; Skeletal related events; Src

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ALENDRONIC ACID; AMGN 0007; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; BOSUTINIB; CATHEPSIN K; CHEMOKINE RECEPTOR CXCR4; CHLORIDE CHANNEL; DASATINIB; DENOSUMAB; ENDOTHELIN 1; INTEGRIN; KX 2391; MK 0429; ODANACATIB; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PARATHYROID HORMONE RELATED PROTEIN; PLACEBO; PROTEIN TYROSINE KINASE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SARACATINIB; SCLEROSTIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; WNT PROTEIN; ZOLEDRONIC ACID;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE PHASE RESPONSE; ASTHENIA; BONE MARROW; BONE METASTASIS; BONE PAIN; BONE TURNOVER; CANCER CELL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; HYPOCALCEMIA; HYPOPHOSPHATEMIA; JAW OSTEONECROSIS; MOLECULARLY TARGETED THERAPY; NAUSEA; NONHUMAN; OSSIFICATION; OSTEOCLAST; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE AND BONES; BONE NEOPLASMS; BONE RESORPTION; CATHEPSIN K; HUMANS; OSTEOGENESIS; PAIN; RANK LIGAND; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 79959979494     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711796391660     Document Type: Review

References (219)

1. Coleman, R. E. Should biphosphonates be the treatment of choice for metastatic bone disease? Semin Oncol., 2001, 28, 35-41. (Pubitemid 32844927)
2. Ecker, R. D.; Endo, T.; Wetjen, N. M.; Krauss, W. E. Diagnosis and treatment of vertebral column metastases. Mayo Clin Proc., 2005, 80, 1177-1186. (Pubitemid 41233355)
3. Mercadante, S.; Fulfaro, F. Management of painful bone metastases. Curr Opin Oncol., 2007, 19, 308-314. (Pubitemid 46883518)
4. Goldberg, G.; Morrison, R. Pain management in hospitalized cancer patients: a systematic review. J Clin Oncol., 2007, 25, 1792-1801. (Pubitemid 46797963)
5. Baron, R.; Ferrari, S.; Russell, R. G. Denosumab and bisphosphonates: Different mechanisms of action and effects. Bone., 2010, Dec. 9. [Epub ahead of print]
6. Machado, M.; Cruz, L. S.; Tannus, G.; Fonseca M. Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials. Clin Ther., 2009, 31, 962-979.
7. Gralow, J.; Tripathy, D. Managing metastatic bone pain: the role of biphosphonates. J Pain Symptom Manage. 2007, 33, 462-472 (Pubitemid 46482947)
8. Coleman, R. E. Risks and benefits of bisphosphonates. Br J Cancer., 2008, 3;98, 1736-1740. (Pubitemid 351748847)
9. Neville-Webbe, H. L.; Coleman, R. E. Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease. Eur J Cancer., 2010, 46, 1211-1222.
10. Yau, V.; Chow, E.; Davis, L.; Danjoux, C. Pain management in cancer patients with bone metastases remains a challenge. J Pain Symptom Manage., 2004, 27, 1-3. (Pubitemid 38050241)
11. Le Gall, C.; Bonnelye, E.; Clézardin, P. Cathepsin K inhibitors as treatment of bone metastasis. Curr Opinion Support Palliative Care., 2008, 2, 218-222.
12. Paget, S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev., 1989, 8, 98-101.
13. Sterling, J. A.; Edwards, J. R.; Martin, T. J.; Mundy, G. R. Advances in the biology of bone metastasis: how the skeleton affects tumor behavior. Bone., 2011, 48, 6-15.
14. Coleman, R. E.; Guise, T. A.; Lipton, A.; Roodman, G. D.; Berenson, J. R.; Body, J. J.; Boyce, B. F.; Calvi, L. M.; Hadji, P.; McCloskey, E. V.; Saad, F.; Smith, M. R.; Suva, L. J.; Taichman, R. S.; Vessella, R. L.; Weilbaecher, K. N. Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin Cancer Res., 2008, 14, 6387-6395.
15. Bogado, C. E.; Zanchetta, M. B.; Boailchuk, J. A.; Massari, F. E.; Zanchetta, J. R. Denosumab: What's new? Curr Osteoporos Rep., 2011, 9, 12-9.
16. Takayanagi, H. Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol., 2009, 5, 667-676.
17. Rachner, T. D.; Benad, P.; Rauner, M.; Goettsch, C.; Singh, S. K.; Schoppet, M.; Hofbauer, L. C. Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis. J Cell Biochem., 2009, 108, 106-116.
18. Roodman, G. D.; Dougall, W. C. RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev., 2008, 34, 92-101. (Pubitemid 351181016)
19. Luger, N. M.; Honore, P.; Sabino, M. A.; Schwei, M. J.; Rogers, S. D.; Mach, D. B.; Clohisy, D. R.; Mantyh, P. W. Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res., 2001, 61, 4038-4047. (Pubitemid 32720968)
20. Body, J. J.; Greipp, P.; Coleman, R. E.; Facon, T.; Geurs, F.; Fermand, J. P.; Harousseau, J. L.; Lipton, A.; Mariette, X.; Williams, C. D.; Nakanishi, A.; Holloway, D.; Martin, S. W.; Dunstan, C. R.; Bekker, P. J. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer., 2003, 97, 887-892. (Pubitemid 36125828)
21. Neville-Webbe, H. L.; Cross, N. A.; Eaton, C. L.; Nyambo, R.; Evans, C. A.; Coleman, R. E.; Holen, I. Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat., 2004, 86, 269-279. (Pubitemid 39070969)
22. Lamoureux, F.; Moriceau, G.; Picarda, G.; Rousseau, J.; Trichet, V.; Rédini, F. et al. Regulation of osteoprotegerin pro-or anti-tumoral activity by bone tumor microenvironment. Biochim Biophys Acta., 2010, 1805, 17-24.
23. Reddy, G. K.; Mughal, T. I.; Roodman, G. D. Novel approaches in the management of myeloma-related skeletal complications. Support Cancer Ther., 2006, 4, 15-8.
24. Kostenuik, P. J.; Nguyen, H. Q.; McCabe, J.; Warmington, K. S.; Kurahara, C.; Sun, N.; Chen, C.; Li, L.; Cattley, R. C.; Van, G.; Scully, S.; Elliott, R.; Grisanti, M.; Morony, S.; Tan, H. L.; Asuncion, F.; Li, X.; Ominsky, M. S.; Stolina, M.; Dwyer, D.; Dougall, W. C.; Hawkins, N.; Boyle, W. J.; Simonet, W. S.; Sullivan, J. K. Denosumab, a fully humanmonoclonal antibody to RANKL, inhibitsboneresorption and increases BMD in knock-inmicethat express chimeric (murine/human) RANKL. J BoneMinerRes., 2009, 24, 182-195.
25. Pierroz, D. D.; Bonnet, N.; Baldock, P. A.; Ominsky, M. S.; Stolina, M.; Kostenuik, P. J.; Ferrari, S. L. Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL. J Biol Chem., 2010, 285, 28164-28173.
26. Hofbauer, L. C.; Zeitz, U.; Schoppet, M.; Skalicky, M.; Schüler, C.; Stolina, M.; Kostenuik, P. J.; Erben, R. G. Prevention of glucocorticoid- induced bone loss in mice by inhibition of RANKL. Arthritis Rheum., 2009, 60, 1427-1437.
27. Gerstenfeld, L. C.; Sacks, D. J.; Pelis, M.; Mason, Z. D.; Graves, D. T.; Barrero, M.; Ominsky, M. S.; Kostenuik, P. J.; Morgan, E. F.; Einhorn, T. A. Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. J BoneMinerRes., 2009, 24, 196-208.
28. Bone, H. G.; Bolognese, M. A.; Yuen, C. K.; Kendler, D. L.; Miller, P. D.; Yang, Y. C.; Grazette, L.; San Martin, J.; Gallagher, J. C. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab., 2008, 93, 2149-2157. (Pubitemid 351831529)
29. Cummings, S. R.; San Martin, J.; McClung, M. R.; Siris, E. S.; Eastell, R.; Reid, I. R.; Delmas, P.; Zoog, H. B.; Austin, M.; Wang, A.; Kutilek, S.; Adami, S.; Zanchetta, J.; Libanati, C.; Siddhanti, S.; Christiansen, C. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med., 2009, 361, 756-765.
30. Brown, J. P.; Prince, R. L.; Deal, C.; Recker, R. R.; Kiel, D. P.; de Gregorio, L. H.; Hadji, P.; Hofbauer, L. C.; Alvaro-Gracia, J. M.; Wang, H.; Austin, M.; Wagman, R. B.; Newmark, R.; Libanati, C.; San Martin, J.; Bone, H. G. Comparison of the Effect of Denosumab and Alendronate on Bone Mineral Density and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial. J Bone Miner Res., 2009, 14, 1-34.
31. Body, J. J.; Facon, T.; Coleman, R. E.; Lipton, A.; Geurs, F.; Fan, M.; Holloway, D.; Peterson, M. C.; Bekker, P. J. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res., 2006, 12, 1221-1228. (Pubitemid 43342512)
32. Lipton, A.; Steger, G. G.; Figueroa, J.; Alvarado, C.; Solal-Celigny, P.; Body, J. J.; de Boer, R.; Berardi, R.; Gascon, P.; Tonkin, K. S.; Coleman, R. E.; Paterson, A. H.; Gao, G. M.; Kinsey, A. C.; Peterson, M. C.; Jun, S. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res., 2008, 14, 6690-6696.
33. Fizazi, K.; Lipton, A.; Mariette, X.; Body, J. J.; Rahim, Y.; Gralow, J. R.; Gao, G.; Wu, L.; Sohn, W.; Jun, S. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol., 2009, 27, 1564-1571.
34. Body, J. J.; Lipton, A.; Gralow, J.; Steger, G. G.; Gao, G.; Yeh, H.; Fizazi, K. Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. J Bone Miner Res., 2010, 25, 440-446.
35. Fizazi, K.; Bosserman, L.; Gao, G.; Skacel, T.; Markus, R. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. J Urol., 2009, 182, 509-515.
36. Henry, D. H.; Costa, L.; Goldwasser F.; Hirsh, V.; Hungria, V.; Prausova, J.; Scagliotti G. V.; Sleeboom, H.; Spencer, A.; Vadhan-Raj, S.; von Moos, R.; Willenbacher, W.; Woll, P. J.; Wang, J.; Jiang, Q.; Jun. S.; Dansey R.; Yeh H. Randomized, double-blind study of denosumab versus zolendronic acid in the treatment of bone metastases in paients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol., 2011, 29, 1125-1132.
37. Stopeck, A. T.; Lipton, A.; Body, J. J.; Steger, G. G.; Tonkin, K.; de Boer, R. H.; Lichinitser, M.; Fujiwara, Y.; Yardley, D. A.; Viniegra, M.; Fan, M.; Jiang, Q.; Dansey, R.; Jun, S.; Braun, A. Denosumab compared with zolendronic acid for the treatment of bone metastases in patients with breast cancer: a randomized, double-blind study. J Clin Oncol., 2010, 28, 5132-5139.
38. Wilson, S. R.; Peters, C.; Saftig, P.; Brömme, D. Cathepsin K activitydependent regulation of osteoclast actin ring formation and bone resorption. J Biol Chem., 2009, 284, 2584-2592.
39. Littlewood-Evans, A. J.; Bilbe, G.; Bowler, W. B.; Farley, D.; Wlodarski, B.; Kokubo, T.; Inaoka, T.; Sloane, J.; Evans, D. B.; Gallagher, J. A. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res., 1997, 57, 5386-5390. (Pubitemid 27516378)
40. Kleer, C. G.; Bloushtain-Qimron, N.; Chen, Y. H.; Carrasco, D.; Hu, M.; Yao, J. Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression. Clin Cancer Res., 2008, 14, 5357-5367.
41. Brubaker, K. D.; Vessella, R. L.; True, L. D.; Thomas, R.; Corey, E. Cathepsin K mRNA andprotein expression in prostate cancer progression. J Bone Miner Res., 2003, 18, 222-230. (Pubitemid 36125914)
42. Le Gall, C.; Bellahencene, A.; Bonnelye, E.; Gasser, J. A.; Castronovo, V.; Green, J. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res., 2007, 67, 9894-902. (Pubitemid 47621238)
43. Lewiecki, E. M. Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling. I Drugs., 2009, 12, 799-809.
44. Stoch, S. A.; Zajic, S.; Stone, J.; Miller, D. L.; Van Dyck, K.; Gutierrez, M. J.; De Decker, M.; Liu, L.; Liu, Q.; Scott, B. B.; Panebianco, D.; Jin, B.; Duong, L. T.; Gottesdiener, K.; Wagner, J. A. Effect of the Cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled Phase I studies. Clin Pharmacol Ther, 2009, 86, 175-182.
45. Jensen, A. B.; Wynne, C.; Ramirez, G.; He, W.; Song, Y.; Berd, Y.; Wang, H.; Mehta, A.; Lombardi, A. The Cathepsin K inhibitor odanacatib suppresses one resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial. Clin Breast Cancer., 2010;10, 452-458.
46. Yeatman, T. J. A renaissance for SRC. Nat Rev Cancer., 2004, 4, 470-80. (Pubitemid 38745532)
47. Aleshin, A.; Finn R. S. SRC: a century of science brought to the clinic. Neoplasia., 2010, 12, 599-607.
48. Kanda, S.; Miyata, Y.; Kanetake, H.; Smithgall, T. E. Non-receptor proteintyrosine kinases as molecular targets for antiangiogenic therapy. Int J Mol Med., 2007, 20, 113-121.
49. Saad, F.; Lipton, A. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat Rev., 2010, 36, 177-184.
50. Myoui, A.; Nishimura, R.; Williams, P. J.; Hiraga, T.; Tamura, D.; Michigami, T.; Mundy, G. R.; Yoneda, T. C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res., 2003, 63, 5028-5033. (Pubitemid 37022641)
51. Zou, D.; Yoon, HS.; Anjomshoaa, A.; Perez, D.; Fukuzawa, R.; Guilford, P.; Humar, B. Increased levels of active c-Src distinguish invasive from in situ lobular lesions. Breast Cancer Res., 2009, 11, R45.
52. Jallal, H.; Valentino, M. L.; Chen, G.; Boschelli, F.; Ali, S.; Rabbani, S. A. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res., 2007, 67, 1580-1588. (Pubitemid 46383382)
53. Finn, R. S. Targeting Src in breast cancer. Ann Oncol., 2008, 19, 1379-1386.
54. Edwards J. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer. Expert Opin Investig Drugs., 2010, 19, 605-614.
55. Yang, J. C.; Bai, L.; Yap, S.; Gao, A. C.; Kung, H. J.; Evans C. P. Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model. Mol Cancer Ther., 2010, 9, 1629-1637.
56. Koreckij, T.; Nguyen, H.; Brown, L. G.; Yu, E. Y.; Vessella, R. L.; Corey, E. Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br J Cancer., 2009, 101, 263-268.
57. Rabbani, S. A.; Valentino, M. L.; Arakelian, A.; Ali, S.; Boschelli, F. SKI-606 (Bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasis. Mol Cancer Ther., 2010, 9, 1147-1157.
58. Yu, E. Y.; Wilding, G.; Posadas, E.; Gross, M.; Culine, S.; Massard, C. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res., 2009, 15, 7421-7428.
59. http://clinicaltrials.gov. Accessed January 2011. NCT00410813.
60. http://clinicaltrials.gov. Accessed January 2011. NCT00566618.
61. http://clinicaltrials.gov. Accessed January 2011. NCT00936975.
62. http://clinicaltrials.gov. Accessed January 2011. NCT00558272.
63. http://clinicaltrials.gov. Accessed January 2011. NCT01144481.
64. http://clinicaltrials.gov. Accessed January 2011. NCT00319254.
65. http://clinicaltrials.gov. Accessed January 2011. NCT01074138.
66. Rosenthal, M. A.; Davidson, P.; Rolland, F.; Campone, M.; Xue, L.; Han, T. H.; Mehta, A.; Berd, Y.; He, W.; Lombardi, A. Evaluation of the safety, pharmacokinetics and treatment effects of an alpha (nu) beta (3) integrin inhibitor on bone turnover and disease activity in men with hormonerefractory prostate cancer and bone metastases. Asia Pac J Clin Oncol., 2010, 61, 42-48.
67. Harms, J. F.; Welch, D. R.; Samant, R. S.; Shevde, L. A.; Miele, M. E.; Babu, G. R.; Goldberg, S. F.; Gilman, V. R.; Sosnowski, D. M.; Campo, D. A.; Gay, C. V.; Budgeon, L. R.; Mercer, R.; Jewell, J.; Mastro, A. M.; Donahue, H. J.; Erin, N.; Debies, M. T.; Meehan, W. J.; Jones, A. L.; Mbalaviele, G.; Nickols, A.; Christensen, N. D.; Melly, R.; Beck, L. N.; Kent, J.; Rader, R. K.; Kotyk, J. J.; Pagel, M. D.; Westlin, W. F.; Griggs, D. W. A small molecule antagonist of the alpha (v) beta3 integrin suppresses MDA-MB-435 skeletal metastasis. Clin Exp Metastasis., 2004, 21, 119-128. (Pubitemid 38988085)
68. Nakamura, I.; Duong, le T.; Rodan, S. B.; Rodan, GA. Involvement of alpha (v) beta3 integrins in osteoclast function. J Bone Miner Metab., 2007, 25, 337-344. (Pubitemid 350063834)
69. Gramoun, A.; Shorey, S.; Bashutski, J. D.; Dixon, S. J.; Sims, S. M.; Heersche, J. N.; Manolson, M. F. Effects of Vitaxin, a novel therapeutic in trial for metastatic bone tumors, on osteoclast functions in vitro. J Cell Biochem., 2007, 102, 341-352. (Pubitemid 47519408)
70. Tagliabue, E.; Ghirelli, C.; Squicciarini, P.; Aiello, P.; Colnaghi, M. I.; Manard, S. Prognostic value of alpha 6 beta 4 integrin expression in breast carcinomas is affected by laminin production from tumor cells. Clin Cancer Res., 1998, 4, 407-410. (Pubitemid 28122756)
71. King, T. E.; Pawar, S. C.; Majuta, L.; Sroka, I. C.; Wynn, D.; Demetriou, M. C.; Nagle, R. B.; Porreca, F.; Cress, A. E. The role of alpha 6 integrin in prostate cancer migration and bone pain in a novel xenograft model. PLoS One., 2008, 3, e3535.
72. Ports, M. O.; Nagle, R. B.; Pond, G. D.; Cress, A. E. Extracellular engagement of alpha6 integrin inhibited urokinase-type plasminogen activator-mediated cleavage and delayed human prostate bone metastasis. Cancer Res., 2009, 69, 5007-5014.
73. Henriksen, K.; Sorensen, M. G.; Jensen, V. K.; Dziegiel, M. H.; Nosjean, O.; Karsdal, M. A. Ion transporters involved in acidification of the resorption lacuna in osteoclasts. Calcif Tissue Int., 2008, 83, 230-242.
74. Neutzsky-Wulff, A. V.; Sorensen, M. G.; Kocijancic, D.; Leeming, D. J.; Dziegiel, M. H.; Karsdal, M. A.; Henriksen, K. Alterations in osteoclast function and phenotype induced by different inhibitors of bone resorption-implications for osteoclast quality. BMC Musculoskelet Disord., 2010, 11, 109.
75. Supanchart, C.; Kornak, U. Ion channels and transporters in osteoclasts. Arch Biochem Biophys., 2008, 473, 161-165.
76. Kornak, U.; Kasper, D.; Bosl, M. R.; Kaiser, E.; Schweizer, M.; Schulz, A.; Friedrich, W.; Delling, G.; Jentsch, T. J. Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell., 2001, 104, 205-215. (Pubitemid 32174837)
77. Whyte, M. P.; Kempa, L. G.; McAlister, W. H.; Zhang, F.; Mumm, S.; Wenkert, D. Elevated serum lactate dehydrogenase isoenzymes and aspartate transaminase distinguish Albers-Schonberg disease (Chloride Channel 7 Deficiency Osteopetrosis) among the sclerosing bone disorders. J Bone Miner Res., 2010, 25, 2515-2526.
78. Schaller, S.; Henriksen, K.; Sveigaard, C.; Heegaard, A. M.; Holix, N.; Stahlhut, M.; Ovejero, M. C.; Johansen, J. V.; Solberg, H.; Andersen, T. L.; Hougaard, D.; Berryman, M.; Shiødt, C. B.; Sørensen, B. H.; Lichtenberg, J.; Christophersen, P.; Foged, N. T.; Delaissé, J. M.; Engsig, M. T.; Karsdal, M. A. The chloride channel inhibitor NS3736 [corrected] prevents bone resorption in ovariectomized rats without changing bone formation. J Bone Miner Res., 2004, 19, 1144-1153. (Pubitemid 41110567)
79. Bowman, E. J.; Siebers, A.; Altendorf, K. Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells. Proc Natl Acad Sci USA., 1988, 85, 7972-7976.
80. Sorensen, M. G.; Henriksen, K.; Neutzsky-Wulff, A. V.; Dziegiel, M. H.; Karsdal, M. A. Diphyllin, a novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacunae and bone resorption. J Bone Miner Res., 2007, 22, 1640-1648. (Pubitemid 351229334)
81. Guise, T. A. Parathyroid hormone-related protein and bone metastases. Cancer., 1997, 80, 1572-1580. (Pubitemid 27444029)
82. Akhtari, M.; Mansuri, J.; Newman, K. A.; Guise, T. M.; Seth, P. Biology of breast cancer bone metastasis. Cancer Biol Ther., 2008, 7, 3-9.
83. Testini, M.; Gurrado, A.; Lissidini, G.; Piccinni, G.; Greco, L.; Basile, F.; Biondi, A. Parathyroid hormone-related peptide and primary hyperparathyroidism. Front Biosci (Schol Ed)., 2010, 2, 299-312.
84. Powell, G. J.; Southby, J.; Danks, J. A.; Stillwell, R. G.; Hayman, J. A.; Henderson, M. A.; Bennett, R. C.; Martin, T. J. Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res., 1991, 51, 3059-3061.
85. Bouizar, Z.; Spyratos, F.; De vernejoul, M. C. The parathyroid hormonerelated protein (PTHrP) gene: use of downstream TATA promotor and PTHrP 1-139 coding pathways in primary breast cancers vary with the occurrence of bone metastasis. J Bone Miner Res., 1999, 14, 406-414. (Pubitemid 29106717)
86. Bundred, N. J.; Walker, R. A.; Ratcliffe, W. A.; Warwick, J.; Morrison, J. M.; Ratcliffe, J. G. Parathyroid hormone related protein and skeletal morbidity in breast cancer. Eur J Cancer., 1992, 28, 690-692.
87. Kissin, M. W.; Henderson, M. A.; Danks, J. A.; Hayman, J. A.; Bennett, R. C.; Martin, T. J. Parathyroid hormone related protein in breast cancers of widely varying prognosis. Eur J Surg Oncol, 1993, 19, 134-142. (Pubitemid 23173153)
88. Liapis, H.; Crouch, E. C.; Grosso, L. E.; Kitazawa, S.; Wick, M. R. Expression of parathyroid like protein in normal, proliferative, and neoplastic human breast tissues. Am J Pathol., 1993, 143, 1169-1178. (Pubitemid 24070559)
89. Linforth, R.; Anderson, N.; Hoey, R.; Nolan, T.; Downey, S.; Brady, G.; Ashcroft, L.; Bundred, N. Coexpression of parathyroid hormone related protein and its receptor in early breast cancer predicts poor patient survival. Clin Cancer Res., 2002, 8, 3172-3177. (Pubitemid 35155027)
90. Southby, J.; Kissin, M. W.; Danks, J. A.; Hayman, J. A.; Moseley, J. M; Henderson, M. A; Bennett, R. C.; Martin, T. J. Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer. Cancer Res., 1990, 50, 7710-7716.
91. Henderson, M. A.; Danks, J. A.; Slavin, J. L.; Byrnes, G. B.; Choong, P. F.; Spillane, J. B.; Hopper, J. L.; Martin, T. J. et al. Parathyroid hormone-related protein localization in breast cancers predict improved prognosis. Cancer Res., 2006, 66, 2250-2256.
92. Suda, T.; Takahashi, N.; Udagawa, N.; Jimi, E.; Gillespie, M. T.; Martin, T. J. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev., 1999, 20, 345-357. (Pubitemid 30649812)
93. Thomas, R. J.; Guise, T. A.; Yin, J. J.; Elliott, J.; Horwood, N. J.; Martin, T. J.; Gillespie, M. T. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology., 1999, 140, 4451-4458. (Pubitemid 30666108)
94. Miki, T.; Yano, S.; Hanibuchi, M.; Kanematsu, T.; Muguruma, H.; Sone, S. Parathyroid hormone-related protein (PTHrP) is responsible for production of bone metastasis, but not visceral metastasis, by human small cell lung cancer SBC-5 cells in natural killer cell-depleted SCID mice. Int J Cancer., 2004, 108, 511-515. (Pubitemid 38036650)
95. Yamada, T.; Muguruma, H.; Yano, S.; Ikuta, K.; Ogino, H.; Kakiuchi, S.; Hanibuchi, M.; Uehara, H.; Nishioka, Y.; Sone, S. Intensification therapy with anti-parathyroid hormone-related protein antibody plus zoledronic acid for bone metastases of small cell lung cancer cells in severe combined immunodeficient mice. Mol Cancer Ther., 2009, 8, 119-126.
96. Nelson JB. Endothelin receptor antagonists. World J Urol., 2005, 23, 19-27. (Pubitemid 40425167)
97. Carducci, M. A.; Jimeno, A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res., 2006, 12, 6296s-6300s. (Pubitemid 44703806)
98. Nelson, J. B.; Hedican, S. P.; George, D. J.; Reddi, A. H.; Piantadosi, S.; Eisenberger, M. A.; Simons, J. W. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med., 1995, 1, 944-949.
99. Santini, D.; Galluzzo, S.; Zoccoli, A.; Pantano, F.; Fratto, M. E.; Vincenzi, B.; Lombardi, L.; Gucciardino, C.; Silvestris, N.; Riva, E.; Rizzo, S.; Russo, A.; Maiello, E.; Colucci, G.; Tonini, G. New molecular targets in bone metastases. Cancer Treat Rev., 2010, 36.
100. Bagnato, A.; Spinella, F. Emerging role of endothelin-1 in tumor angiogenesis. Trends Endocrinol Metab., 2003, 14, 44-50. (Pubitemid 36733931)
101. Nelson, J. B.; Nguyen, S. H.; Wu-Wong, J. R.; Opgenorth, T. J.; Dixon, D. B.; Chung, L. W. K.; Inoue, N. New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology., 1999, 53, 1063-1069. (Pubitemid 29196330)
102. Raffa, R. B.; Schupsky, J. J.; Martinez, R. P.; Jacoby, H. I. Endothelin-1 induced nociception. Life Sci., 1991, 49, 61-65.
103. Hans, G.; Deseure, K.; Adriaensen, H. Endothelin-1-induced pain and hyperalgesia: a review of pathophysiology, clinical manifestations and future therapeutic options. Neuropeptides., 2008, 42, 119-132.
104. Carducci, M. A.; Saad, F.; Abrahamsson, P. A.; Dearnaley, D. P.; Schulman, C. C.; North, S. A.; Sleep, D. J.; Isaacson, J. D.; Nelson, J. B. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer., 2007, 110, 1959-1966. (Pubitemid 350036854)
105. Nelson, J. B.; Love, W.; Chin, J. L.; Saad, F.; Schulman, C. C.; Sleep, D. J.; Qian, J.; Steinberg, J.; Carducci, M. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer., 2008, 113, 2478-2487.
106. Armstrong, A. J.; Creel, P.; Turnbull, J.; Moore, C.; Jaffe, T. A.; Haley, S.; Petros, W.; Yenser, S.; Gockerman, J. P.; Sleep, D.; Hurwitz, H.; George, D. J. A phase I-II study of docetaxel and atrasentan in men with castrationresistant metastatic prostate cancer. Clin Cancer Res.; 2008, 14, 6270-6276.
107. http://clinicaltrials.gov Accessed January 2011. NCT00134056.
108. Warren, R.; Liu, G. ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer. Expert Opin Investig Drugs., 2008, 17, 1237-1245.
109. Fukuroda, T.; Fujikawa, T.; Ozaki, S.; Ishikawa, K.; Yano, M.; Nishikibe, M. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun., 1994, 199, 1461-1465.
110. James, N. D.; Caty, A.; Borre, M.; Zonnenberg, B. A.; Beuzeboc, P.; Morris, T.; Phung, D.; Dawson, N. A. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol., 2009, 55, 1112-1123.
111. James, N. D.; Caty, A.; Payne, H.; Borre, M.; Zonnenberg, B. A.; Beuzeboc, P.; McIntosh, S.; Morris, T.; Phung, D.; Dawson, N. A. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial. BJU Int., 2010, 106, 966-973.
112. Schelman, W. R.; Liu, G.; Wilding, G.; Morris, T.; Phung, D.; Dreicer, R. A phase I study of zibotentan (ZD4054) in patients with metastatic, castrateresistant prostate cancer. Invest New Drugs., 2011, 29, 118-125.
113. http://clinicaltrials.gov. Accessed January 2011. NCT00617669.
114. Chouaid, C.; Nathan, F.; Pemberton, K.; Morris, T. A phase II, randomized, multicenter study to assess the efficacy, safety, and tolerability of zibotentan (ZD4054) in combination with pemetrexed in patients with advanced nonsmall cell lung cancer. Cancer Chemother Pharmacol. 2011, 67, 1203-1208.
115. http://clinicaltrials.gov. Accessed January 2011. NCT01205711; NCT01134497; NCT00929162.
116. Brunkow, M. E.; Gardner, J. C.; Van Ness, J.; Paeper, B. W.; Kovacevich, B. R.; Proll, S.; Skonier, J. E.; Zhao, L.; Sabo, P. J.; Fu, Y.; Alisch, R. S.; Gillett, L.; Colbert, T.; Tacconi, P.; Galas, D.; Hamersma, H.; Beighton, P.; Mulligan, J. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet., 2001, 68, 577-589. (Pubitemid 32202753)
117. Moester, M. J.; Papapoulos, S. E.; Löwik, C. W.; van Bezooijen, R. L. Sclerostin: current knowledge and future perspectives. Calcif Tissue Int., 2010, 87, 99-107.
118. Gardner, J. C.; van Bezooijen, R. L.; Mervis, B.; Hamdy, N. A.; Löwik, C. W.; Hamersma, H.; Beighton, P.; Papapoulos, S. E. Bone mineral density in sclerosteosis; affected individuals and gene carriers. J Clin Endocrinol Metab., 2005, 90, 6392-6395. (Pubitemid 41759290)
119. van Bezooijen, R. L.; ten Dijke, P.; Papapoulos, S. E.; Löwik, C. W. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev., 2005, 16, 319-327. (Pubitemid 40910321)
120. Li, X.; Ominsky, M. S.; Niu, Q. T.; Sun, N.; Daugherty, B.; D'Agostin, D.; Kurahara, C.; Gao, Y.; Cao, J.; Gong, J.; Asuncion, F.; Barrero, M.; Warmington, K.; Dwyer, D.; Stolina, M.; Morony, S.; Sarosi, I.; Kostenuik, P. J.; Lacey, D. L.; Simonet, W. S.; Ke, H. Z.; Paszty, C. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res., 2008, 23, 860-869. (Pubitemid 351768804)
121. Poole, K. E.; van Bezooijen, R. L.; Loveridge, N.; Hamersma, H.; Papapoulos, S. E.; Löwik, C. W.; Reeve, J. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J., 2005, 19, 1842-1844. (Pubitemid 41598769)
122. Lin, C.; Jiang, X.; Dai, Z.; Guo, X.; Weng, T.; Wang, J.; Li, Y.; Feng, G.; Gao, X.; He, L. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J Bone Miner Res., 2009, 24, 1651-1661.
123. Li, X.; Ominsky, M. S.; Warmington, K. S.; Morony, S.; Gong, J.; Cao, J.; Gao, Y; Shalhoub, V.; Tipton, B.; Haldankar, R.; Chen, Q.; Winters, A.; Boone, T.; Geng, Z.; Niu, Q. T.; Ke, H. Z.; Kostenuik, P. J.; Simonet, W. S.; Lacey, D. L.; Paszty, C. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res., 2009, 24, 578-588.
124. Eddleston, A.; Marenzana, M.; Moore, A. R.; Stephens, P.; Muzylak, M.; Marshall, D.; Robinson, M. K. A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis. J Bone Miner Res., 2009, 24, 1662-1671.
125. Padhi, D.; Jang, G.; Stouch, B.; Fang, L.; Posvar, E. Single-dose, placebocontrolled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res., 2011, 26, 19-26.
126. http://clinicaltrials.gov Accessed January 2011. NCT00896532
127. http://clinicaltrials.gov. Accessed January 2011 NCT01081678; NCT00907296.
128. Clausen, K. A.; Blish, K. R.; Birse, C. E.; Triplette, M. A.; Kute, T. E.; Russell, G. B.; D'Agostino, R. B.; Miller, L. D.; Torti, F. M.; Torti, S. V. SOSTDC1 differentially modulates Smad and beta-catenin activation and is downregulated in breast cancer. Breast Cancer Res Treat., 2010, Nov. 27 [Epub ahead of print]
129. Bonafoux, D.; Lee, W. C. Strategies for TGF-beta modulation: a review of recent patents. Expert Opin Ther Pat., 2009, 19, 1759-1769.
130. Derynck, R.; Akhurst, R. J.; Balmain, A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet., 2001, 29, 117-129. (Pubitemid 32952643)
131. Kang, Y.; He, W.; Tulley, S.; Gupta, G. P.; Serganova, I.; Chen, C. R.; Manova-Todorova, K.; Blasberg, R.; Gerald, W. L.; Massagué, J. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc. Natl Acad. Sci., 2005, 102, 13909-13914. (Pubitemid 41377677)
132. http://clinicaltrials.gov. Accessed January 2011. NCT00844064; NCT00761280; NCT00431561.
133. Pearsall, R. S.; Canalis, E.; Cornwall-Brady, M.; Underwood, K. W.; Haigis, B.; Ucran, J.; Kumar, R.; Pobre, E.; Grinberg, A.; Werner, E. D.; Glatt, V.; Stadmeyer, L.; Smith, D.; Seehra, J.; Bouxsein, M. L. A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. Proc Natl Acad Sci U S A., 2008, 105, 7082-7087. (Pubitemid 351754533)
134. Lotinun, S.; Pearsall, R. S.; Davies, M. V.; Marvell, T. H.; Monnell, T. E.; Ucran, J. A soluble activinreceptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys. Bone., 2010, 46, 1082-1088.
135. Ruckle, J.; Jacobs, M.; Kramer, W.; Pearsall, A. E.; Kumar, R.; Underwood, K. W.; Seehra, J.; Yang, Y.; Condon, C. H.; Sherman, M. L. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res., 2009, 24, 744-752.
136. http://clinicaltrials.gov. Accessed January 2011 NCT00747123.
137. Richard, C. L.; Blay, J. CXCR4 in Cancer and Its Regulation by PPARgamma. P PAR Res., 2008;2008:769413
138. Zlotnik, A. Chemokines in neoplastic progression. Semin Cancer Biol., 2004, 14, 181-185. (Pubitemid 38586743)
139. Balkwill F. The significance of cancer cell expression of the chemokine
140. Andre, F.; Xia, W.; Conforti, R.; Wei, Y.; Boulet, T.; Tomasic, G. CXCR4 expression in early breast cancer and risk of distant recurrence. Oncologist., 2009, 14, 1182-1188.
141. Li, Y. M.; Pan, Y.; Wei, Y.; Cheng, X.; Zhou, B. P.; Tan, M.; Zhou, X.; Xia, W.; Hortobagyi, G. N.; Yu, D.; Hung, M. C. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell., 2004, 6, 459-469. (Pubitemid 39469982)
142. Wang, Q.; Diao, X.; Sun, J.; Chen, Z. Regulation of VEGF, MMP-9, and metastasis by CXCR4 in a prostate cancer cell line. Cell Biol Int, 2011, Feb. 10. [Epub ahead of print]
143. Zhao, F. L.; Guo, W. Expression of stromal derived factor-1 (SDF-1) and chemokine receptor (CXCR4) in bone metastasis of renal carcinoma. Mol Biol Rep. 2011, 38, 1039-1045.
144. Hirbe, A. C.; Morgan, E. A.; Weilbaecher, K. N. The CXCR4/SDF-1 chemokine axis: a potential therapeutic target for bone metastases? Curr Pharm Des., 2010, 16, 1284-1290.
145. Huang, E. H.; Singh, B.; Cristofanilli, M.; Gelovani, J.; Wei, C.; Vincent, L.; Cook, K. R.; Lucci, A. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J. Surg. Res., 2009, 155, 231-236.
146. Richert, M. M.; Vaidya, K. S.; Mills, C. N.; Wong, D.; Korz, W.; Hurst, D. R.; Welch, D. R. Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. Oncol. Rep., 2009, 21, 761-767.
147. Hassan, S.; Buchanan, M.; Jahan, K.; Aguilar-Mahecha, A.; Gaboury, L.; Muller, W. J.; Alsawafi, Y.; Mourskaia, A. A.; Siegel, P. M.; Salvucci, O.; Basik, M. CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances theefficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int J Cancer, 2010, Sep. 9. [Epub ahead of print].
148. Singh, B.; Cook, K. R.; Martin, C.; Huang, E. H.; Mosalpuria, K.; Krishnamurthy, S.; Cristofanilli, M.; Lucci, A. Evaluation of a CXCR4 antagonist in a xenograft mouse model of inflammatory breast cancer. Clin Exp Metastasis., 2010, 27, 233-240.
149. Choi, H. Y.; Yong, C. S.; Yoo, B. K. Plerixafor for stem cell mobilization in patients with non-Hodgkin's lymphoma and multiple myeloma. Ann Pharmacother., 2010, 44, 117-126.
150. Kessans, M. R.; Gatesman, M. L.; Kockler, D. R. Plerixafor: a peripheral blood stem cell mobilize. Pharmacotherapy., 2010, 30, 485-492.
151. Cabioglu, N.; Summy, J.; Miller, C.; Parikh, N. U.; Sahin, A. A.; Tuzlali, S.; Pumiglia, K.; Gallick, G. E.; Price, J. E. CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res., 2005, 65, 6493-6497. (Pubitemid 41060680)
152. Rose, A. A.; Siegel, P. M. Emerging therapeutic targets in breast cancer bone metastasis. Future Oncol., 2010, 6, 55-74.
153. Hirbe, A. C.; Rubin, J.; Uluckan, O.; Morgan, E. A.; Eagleton, M. C. Prior JL. Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone. Proc Natl Acad Sci USA., 2007, 104, 14062-14067. (Pubitemid 350003335)
154. Rose, A. A.; Annis, M. G.; Dong, Z.; Pepin, F.; Hallett, M.; Park, M.; Siegel, P. M. ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties. PLoS One., 2010, 5, 12093.
155. Pahl, M. V.; Vaziri, N. D.; Yuan, J.; Adler, S. G. Upregulation of monocyte/macrophage HGFIN (Gpnmb/Osteoactivin) expression in endstage renal disease. Clin J Am Soc Nephrol., 2010, 5, 56-61.
156. Selim, A. A.; Abdelmagid, S. M.; Kanaan, R. A.; Smock, S. L.; Owen, T. A.; Popoff, S. N.; Safadi, F. F. Anti-osteoactivin antibody inhibits osteoblast differentiation and function in vitro. Crit Rev Eukaryot Gene Expr., 2003, 13, 265-275. (Pubitemid 38009175)
157. Chung, J. S.; Bonkobara, M.; Tomihari, M.; Cruz, P. D.; Jr Ariizumi, K. The DC-HIL/syndecan-4 pathway inhibits human allogeneic T-cell responses. Eur J Immunol., 2009, 39, 965-974.
158. Adler, S. Novel kidney injury biomarkers. J Ren Nutr., 2010, 20, 15-8.
159. Rose, A. A.; Pepin, F.; Russo, C.; Abou Khalil, J. E.; Hallett, M.; Siegel, P. M. Osteoactivin promotes breast cancer metastasis to bone. Mol Cancer Res., 2007, 5, 1001-10014.
160. Tse, K. F.; Jeffers, M.; Pollack, V. A.; McCabe, D. A.; Shadish, M. L.; Khramtsov, N. V.; Hackett, C. S.; Shenoy, S. G.; Kuang, B.; Boldog, F. L.; MacDougall, J. R.; Rastelli, L.; Herrmann, J.; Gallo, M.; Gazit-Bornstein, G.; Senter, P. D.; Meyer, D. L.; Lichenstein, H. S.; LaRochelle, W. J. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin Cancer Res., 2006, 12, 1373-1382. (Pubitemid 43342531)
161. Naumovski, L.; Junutula, J. R. Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer. Curr Opin Mol Ther., 2010, 12, 248-257.
162. Pollack, V. A.; Alvarez, E.; Tse, K. F.; Torgov, M. Y.; Xie, S.; Shenoy, S. G.; MacDougall, J. R.; Arrol, S.; Zhong, H.; Gerwien, R. W.; Hahne, W. F.; Senter, P. D.; Jeffers, M. E.; Lichenstein, H. S.; LaRochelle, W. J. Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB. Cancer Chemother Pharmacol., 2007, 60, 423-435. (Pubitemid 46944592)
163. http://clinicaltrials.gov. Accessed January 2011 NCT00704158; NCT00412828.
164. Williams, M. D.; Esmaeli, B.; Soheili, A.; Simantov, R.; Gombos, D. S.; Bedikian, A. Y.; Hwu, P. GPNMB expression in uveal melanoma: a potential for targeted therapy. Melanoma Res., 2010, 20, 184-190.
165. Rose, A. A.; Grosset, A. A.; Dong, Z.; Russo, C.; Macdonald, P. A.; Bertos, N. R.; St-Pierre, Y.; Simantov, R.; Hallett, M.; Park, M.; Gaboury, L.; Siegel, P. M. Glycoprotein non metastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer. in Cancer Res., 2010, 16, 2147-2156.
166. Ciardiello, F.; Tortora, G. EGFR antagonists in cancer treatment. N Engl J Med. 2008, 358, 1160-1174.
167. Hynes, N. E.; Lane, H. A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer., 2005, 5, 341-54. (Pubitemid 40637826)
168. Normanno, N.; De Luca, A.; Aldinucci, D.; Maiello, M. R.; Mancino, M.; D'Antonio, A.; De Filippi, R.; Pinto, A. Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis. Endocr Relat Cancer., 2005, 12, 471-482. (Pubitemid 40896460)
169. Zhu, J.; Jia, X.; Xiao, G.; Kang, Y.; Partridge, N. C.; Qin, L. EGF-like ligands stimulate osteoclastogenesis by regulating expression of osteoclast regulatory factors by osteoblasts: implications for osteolytic bone metastases. J Biol Chem., 2007, 282, 26656-26664. (Pubitemid 47501956)
170. Normanno, N.; Bianco, C.; Strizzi, L.; Mancino, M.; Maiello, M. R.; De Luca, A.; Caponigro, F.; Salomon, D. S. The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets., 2005, 6, 243-257. (Pubitemid 40667793)
171. Lu, X.; Kang, Y. Metalloproteinases and osteoblast EGFR signaling in osteolytic bone metastasis of breast cancer. Cell Cycle., 2009, 8, 3804-3805.
172. Lu, X.; Wang, Q.; Hu, G.; Van Poznak, C.; Fleisher, M.; Reiss, M.; Massagué, J.; Kang, Y. ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev., 2009, 23, 1882-1894.
173. Angelucci, A.; Gravina, G. L.; Rucci, N.; Millimaggi, D.; Festuccia, C.; Muzi, P.; Teti, A.; Vicentini, C.; Bologna, M. Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocr Relat Cancer., 2006, 13, 197-210.
174. Normanno, N.; Gullick, W. J. Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: different mechanisms of action for a novel therapeutic application? Endocr Relat Cancer., 2006, 13, 3-6.
175. von Minckwitz, G.; Jonat, W.; Fasching, P.; du Bois, A.; Kleeberg, U.; Lück, H. J.; Kettner, E.; Hilfrich, J.; Eiermann, W.; Torode, J.; Schneeweiss, A. A multicentre phase II study on gefitinib in taxane-and anthracyclinepretreated metastatic breast cancer. Breast Cancer Res Treat., 2005, 89, 165-172. (Pubitemid 40249050)
176. Zukawa, M.; Nakano, M.; Hirano, N.; Mizuhashi, K.; Kanamori, M. The effectiveness of gefitinib on spinal metastases of lung cancer - report of two cases-. Asian Spine J., 2008, 2, 109-113.
177. Krishnan, V.; Bryant, H. U.; Macdougald, O. A. Regulation of bone mass by Wnt signaling. J Clin Invest., 2006, 116, 1202-1209.
178. Hall, C. L.; Keller, E. T. The role of Wnts in bone metastases. Cancer Metastasis Rev., 2006, 25, 551-558. (Pubitemid 46074998)
179. Logan, C. Y.; Nusse, R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol., 2004, 20, 781-810. (Pubitemid 39488658)
180. Bennett, C. N.; Longo, K. A.; Wright, W. S.; Suva, L. J.; Lane, T. F.; Hankenson KD; MacDougald, O. A. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci U S A., 2005, 102, 3324-3329. (Pubitemid 40328044)
181. Reya, T.; Clevers, H. Wnt signaling in stem cells and cancer. Nature., 2005, 434, 843-850. (Pubitemid 40558990)
182. Bodine, P. V.; Zhao, W.; Kharode, Y. P.; Bex, F. J.; Lambert, A. J.; Goad, M. B. The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol Endocrinol., 2004, 18, 1222-1237. (Pubitemid 38591287)
183. Spencer, G. J.; Utting, J. C.; Etheridge, S. L.; Arnett, T. R.; Genever, P. G. Wnt signaling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. J Cell Sci., 2006, 119, 1283-1296.
184. Giles, R. H.; van Es, J. H.; Clevers, H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta., 2003, 1653, 1-24. (Pubitemid 36627817)
185. Hall, C. L.; Bafico, A.; Dai, J.; Aaronson, S. A.; Keller, E. T. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res., 2005, 65, 7554-7560. (Pubitemid 41297224)
186. Hall, C. L.; Kang, S.; MacDougald, O. A.; Keller, E. T. Role of Wnts in prostate cancer bone metastases. J Cell Biochem., 2006, 97, 661-672.
187. Bu, G.; Lu, W.; Liu, C. C.; Selander, K.; Yoneda, T.; Hall, C.; Keller, E. T.; Li, Y. Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: implication for breast cancer osteolytic bone metastases. Int JCancer., 2008, 123, 1034-1042.
188. Tian, E.; Zhan, F.; Walker, R.; Rasmussen, E.; Ma, Y.; Barlogie, B.; Shaughnessy, J. D. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med., 2003, 349, 2483-2494. (Pubitemid 38010074)
189. Yaccoby, S.; Ling, W.; Zhan, F.; Walker, R.; Barlogie, B.; Shaughnessy, J. D. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood., 2007, 109, 2106-2111. (Pubitemid 46348212)
190. Fulciniti, M.; Tassone, P.; Hideshima, T.; Vallet, S.; Nanjappa, P.; Ettenberg, S. A.; Shen, Z.; Patel, N.; Tai, Y. T.; Chauhan, D.; Mitsiades, C.; Prabhala, R.; Raje, N.; Anderson, K. C.; Stover, D. R.; Munshi, N. C. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood., 2009, 114, 371-379.
191. Heath, D. J.; Chantry, A. D.; Buckle, C. H.; Coulton, L.; Shaughnessy, J. D.; Evans, H. R.; Snowden, J. A.; Stover, D. R.; Vanderkerken, K.; Croucher, P. I. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res., 2009, 24, 425-436.
192. Giuliani, N.; Lisignoli, G.; Colla, S.; Lazzaretti, M.; Storti, P.; Mancini, C. CC-Chemokine ligand 20/macrophage inflammatory protein-3alpha and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions. Cancer Res., 2008, 68, 6840-6850.
193. Abe, M.; Hiura, K.; Wilde, J.; Moriyama, K.; Hashimoto, T.; Ozaki, S.; Wakatsuki, S.; Kosaka, M.; Kido, S.; Inoue, D.; Matsumoto, T. Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood., 2002, 100, 2195-21202.
194. Hashimoto, T.; Abe, M.; Oshima, T.; Shibata, H.; Ozaki, S.; Inoue, D.; Matsumoto, T. Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma. Br J Haematol., 2004, 125, 38-41. (Pubitemid 38453275)
195. Han, J. H.; Choi, S. J.; Kurihara, N.; Koide, M.; Oba, Y.; Roodman, G. D. Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappa B ligand. Blood., 2001, 97, 3349-3353.
196. Choi, S. J.; Kurihara, N.; Oba, Y.; Roodman, G. D. Osteoclast inhibitory peptide 2 inhibits osteoclast formation via its C-terminal fragment. J Bone Miner Res. 2001, 16, 1804-1811. (Pubitemid 32911486)
197. Abe, M,; Hiura, K.; Ozaki, S.; Kido, S.; Matsumoto, T. Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production. J Bone Miner Metab., 2009, 27, 16-23.
198. Oba, Y.; Lee, J. W.; Ehrlich, L. A.; Chung, H. Y.; Jelinek, D. F.; Callander, N. S. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Exp Hematol., 2005, 33, 272-278. (Pubitemid 40261308)
199. Vallet, S.; Raje, N.; Ishitsuka, K.; Hideshima, T.; Podar, K.; Chhetri, S.; et al. MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood., 2007, 110, 3744-3752. (Pubitemid 350159645)
200. Vergunst, C. E.; Gerlag, D. M.; von Moltke, L.; Karol, M.; Wyant, T.; Chi, X; Matzkin, E.; Leach, T.; Tak, P. P. MLN3897 plus methotrexate in patients with rheumatoid arthritis: safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study. Arthritis Rheum., 2009, 60, 3572-3581.
201. Kopan, R.; Ilagan, M. X. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell., 2009, 137, 216-233.
202. Shih, IeM.; Wang, T. L. Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res., 2007, 67, 1879-1882. (Pubitemid 46424200)
203. Ellisen, L.; Bird, J.; West, D.; Soreng, A.; Reynolds, T.; Smith, S.; Sklar, J. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell, 1991, 66, 649-661. (Pubitemid 121001701)
204. Rizzo, P.; Osipo, C; Foreman, K.; Golde, T.; Osborne, B.; Miele, L. Rational targeting of Notch signaling in cancer. Oncogene, 2008, 27, 5124-5131.
205. Miele, L.; Miao, H.; Nickoloff, B. J. NOTCH signaling as a novel cancer therapeutic target. Curr Cancer Drug Targets., 2006, 6, 313-323 (Pubitemid 43961866)
206. Selkoe, D.; Kopan, R. Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. Annu. Rev. Neurosci., 2003, 26, 565-597 (Pubitemid 37064944)
207. Imbimbo, B. P.; Panza, F.; Frisardi, V.; Solfrizzi, V.; D'Onofrio, G.; Logroscino, G.; Seripa, D.; Pilotto, A. Therapeutic intervention for Alzheimer's disease with y-secretase inhibitors: still a viable option? Expert Opin Investig Drugs., 2011, 20, 325-341
208. Curry, C. L.; Reed, L. L.; Golde, T. E.; Miele, L.; Nickoloff, B. J.; Foreman, K. E. Gamma-secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene, 2005, 24, 6333-6344. (Pubitemid 41486467)
209. Hallahan, A. R.; Pritchard, J. I.; Hansen, S.; Benson, M.; Stoeck, J.; Hatton, B. A.; Russel, T. L.; Ellenbogen, R. G.; Bernstein, ID.; Beachy, PA.; Olson, J. M. The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res., 2004, 64, 7794-7800 (Pubitemid 39446912)
210. Huges, D. P How the NOTCH pathway contributes to the ability of osteosarcoma cells to metastasize. Cancer Treat Res., 2009, 152, 479-496.
211. Fong, J. E.; Le Nihouannen, D.; Komarova, S. V. Tumor-supportive and Osteoclastogenic Changes Induced by Breast Cancer-derived Factors Are Reversed by Inhibition of gamma-Secretase. J Biol Chem., 2010, 285, 31427-31434.
212. Sethi, N.; Dai, X.; Winter, C. G.; Kang, Y. Tumor-Derived Jagged1 Promotes Osteolytic Bone Metastasis of Breast Cancer by Engaging Notch Signaling in Bone Cells. Cancer Cell, 2001, 19, 192-205.
213. van Es, J. H.; van Gijn, M. E.; Riccio, O.; van den Born, M.; Vooijs, M.; Begthel, H.; Cozijnsen, M.; Robine, S.; Winton, D. J.; Radtke, F.; Clevers, H. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature, 2005, 435, 959-963. (Pubitemid 40896322)
214. Nefedova, Y; Gabrilovich D. Mechanisms and clinical prospects of Notch inhibitors in the therapy of hematological malignancies. Drug Resist Updat, 2008, 11, 210-218.
215. Sambamurti, K.; Greig, N. H.; Utsuki, T.; Barnwell, E. L.; Sharma, E.; Mazell, C; Bhat, N. R.; Kindly, M. S.; Lahiri, D. K.; Pappolla, M. A. Targets for AD treatment: conflicting messages from y-secretase inhibitors. J Neurochem., 2011, 117, 359-374.
216. Lipton, A. Implications of bone metastases and the benefits of bone-targeted therapy. Semin Oncol, 2010, 37, S15-29.
217. Coleman, R. E.; Lipton, A.; Roodman, G. D.; Guise, T. A.; Boyce, B. F; Brufsky, A. M.; Clezardin, P.; Croucher, PI.; Gralow, J. R.; Hadji, P.; Holen, I.; Mundy, G. R.; Smith, MR.; Suva, L. J. Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev., 2010, 36, 615-620.
218. Coluzzi, F.; Mandatori, I.; Mattia, C. Emerging therapies in metastatic bone pain. Expert Opin Emerg Drugs. 2011, May 5. [Epub ahead of print]
219. Jimenez-Andrade, J. M.; Mantyh, W. G.; Bloom, A. P; Ferng, A. S.; Geffre, C. P; Mantyh, PW. Bone cancer pain. Ann N Y Acad Sci., 2010, 198, 173-181.